



PRECEPTORSHIP IN DIGESTIVE TUMORS

13th & 14th May - 2024 | Barcelona

PRECEPTORSHIP IN DIGESTIVE TUMORS

📅 13th & 14th May - 2024

📍 **Cellex Center**
C/ NATZARET, 115-117 08035
BARCELONA – ESPANYA

☎ +34 93 254 34 50

✉ info@vhio.net

👤 **Coordination: Teresa Macarulla**
Group Leader of VHIO's Gastrointestinal and Endocrine
Tumors Group and Noncolorectal GI Cancer Translational
Research Group

www.vhio.net

Organize:



Sponsors:



PERMANYER
www.permanyer.com

09:45-10:00h	Welcome and introductions Teresa Macarulla	11:20-11:40 h	Treatment Her2 positive disease Marc Díez
10:00-13:00 h	Upper GI Session – advanced Gastric/GEJ adenocarcinoma	11:40-12:00 h	IO toxicities and management in mGC/GEJ adenocarcinoma Daniel Acosta
10:00-10:20 h	Epidemiology and molecular/clinical distinct characteristics of gastric and GE junction cancer Marc Díez	12:00-12:50 h	Clinical Cases from participants – Tumor board. GC/GEJC with a focus on locally advanced disease GC/GEJ Faculty
10:20-10:40 h	Pathology and biomarkers of gastric and GEJC cancer Stefania Landolfi	12:50-13:00 h	Exchange Debate: Unresolved questions from participants
10:40-11:00 h	First Line Treatment Her2 negative Daniel Acosta	13:00-14:30 h	Lunch
11:00-11:20 h	Coffee Break	14:30-16.00 h	Visita phase 1 unit in Vall d'Hebrón University Hospital Daniel López

10:00-13:00 h	LOWER GI SESSION – METASTATIC COLORECTAL CANCER (15 min presentations + 5 min questions/Discussion)		
10:00-10:20 h	VHIO Colon Cancer Program Elena Elez	11:40-12:30 h	Tumor Board CRC Faculty We can cover POL-E, BRAF, HER2. To confirm number of cases and subtypes from the participants
10:20-11:40 h	Addressing the front-line setting in MSS/pMMR mCRC Francesc Salvà Overview, clinical landscape, guidelines recommendations (including recent ESMO updates, biomarkers)	12:30-13:00 h	The role of immunotherapy in BTC Florian Castet
	State of the art in dMMR/MSI-H metastatic Colorectal Cancer Javier Ros The role of IO in mCRC and current challenges: duration of therapy, rechallenge, IO combination therapies	13:00-14:30 h	Lunch
11:00-11:20 h	Coffe break	14:30-15:45 h	Updates from ESMO and ASCO GI Teresa Macarulla
11:20-11:40 h	Is there a room for immunotehrapy in pMMR/MSS colorectal cancer? Iosune Baraibar IO combination therapies, Microbiome, young onset CRC	15:45-16:00 h	Conclusions